Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

The Checkup by Singlecare

AUGUST 31, 2023

Before filling a prescription, check with the insurance company. With a monthly price tag of $1,580, Mounjaro is no exception. As with other premium-priced prescription drugs, the manufacturer, Eli Lilly, offers a patient assistance program and a Mounjaro savings card. Mounjaro can only be purchased at a premium price.

Insurance 98

Insurance Compounding Insurance Coverage Labelling 98

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

The Checkup by Singlecare

SEPTEMBER 7, 2023

Mounjaro (tirzepaptide), manufactured by Eli Lilly Inc., Unfortunately, insurance companies generally won’t cover Mounjaro for unapproved indications like weight loss. Fortunately, drug therapy for diabetes has come a long way. Metformin has long been the first-line therapy for Type 2 diabetes.

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

PharmaShots

MARCH 9, 2023

Present company and time period: Pfizer (2 yrs.) Designation: Chief Medical Officer (CMO) and Head of Worldwide Medical and Safety at Pfizer Previous company: Stanford University (12 yrs. Present company and time period: Sensium Healthcare (6 yrs. Designation: Chief Scientific Officer Previous company: Toumaz UK Ltd. (15

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

European Pharmaceutical Review

MAY 11, 2023

Novartis shared long-term data for its SMA gene therapy in March 2023, which indicated significant long-term motor-milestone achievements in spinal muscular atrophy (SMA). Without this protein, the motor neuron cells shrink and eventually die. This causes debilitating and potentially fatal muscle weakness. Why is it significant? years post-dosing.

FDA 73

FDA 73